JP2023529926A - Ｇｃｎ２阻害剤として有用な４－エチニルピリジン誘導体 - Google Patents
Ｇｃｎ２阻害剤として有用な４－エチニルピリジン誘導体 Download PDFInfo
- Publication number
- JP2023529926A JP2023529926A JP2022576040A JP2022576040A JP2023529926A JP 2023529926 A JP2023529926 A JP 2023529926A JP 2022576040 A JP2022576040 A JP 2022576040A JP 2022576040 A JP2022576040 A JP 2022576040A JP 2023529926 A JP2023529926 A JP 2023529926A
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- group
- halogen
- halogens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2008749.0 | 2020-06-09 | ||
| GBGB2008749.0A GB202008749D0 (en) | 2020-06-09 | 2020-06-09 | Novel compounds |
| PCT/GB2021/051428 WO2021250399A1 (en) | 2020-06-09 | 2021-06-09 | 4-ethynylpyridine derivatives useful as gcn2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023529926A true JP2023529926A (ja) | 2023-07-12 |
| JP2023529926A5 JP2023529926A5 (https=) | 2025-12-04 |
Family
ID=71616023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022576040A Pending JP2023529926A (ja) | 2020-06-09 | 2021-06-09 | Ｇｃｎ２阻害剤として有用な４－エチニルピリジン誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20230271939A1 (https=) |
| EP (1) | EP4161915A1 (https=) |
| JP (1) | JP2023529926A (https=) |
| KR (1) | KR20230058042A (https=) |
| CN (2) | CN116113629B (https=) |
| AU (1) | AU2021289535A1 (https=) |
| BR (1) | BR112022025147A2 (https=) |
| CA (1) | CA3181909A1 (https=) |
| GB (1) | GB202008749D0 (https=) |
| IL (1) | IL298860B1 (https=) |
| MX (1) | MX2022015516A (https=) |
| WO (1) | WO2021250399A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
| GB202104635D0 (en) | 2021-03-31 | 2021-05-12 | Imperial College Innovations Ltd | Methods and compositions for identifying and treating GCN2-dependent cancers |
| GB202118096D0 (en) * | 2021-12-14 | 2022-01-26 | Ip2Ipo Innovations Ltd | Novel compounds |
| GB202403113D0 (en) | 2024-03-04 | 2024-04-17 | Apollo Ap30 Ltd | Novel compounds |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018030466A1 (ja) * | 2016-08-10 | 2018-02-15 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2020210828A1 (en) * | 2019-04-12 | 2020-10-15 | Hibercell, Inc. | (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7037927B2 (en) | 2003-10-16 | 2006-05-02 | Abbott Laboratories | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| US20080146599A1 (en) | 2005-02-01 | 2008-06-19 | Astrazeneca Ab | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity |
| GB0502418D0 (en) | 2005-02-05 | 2005-03-16 | Astrazeneca Ab | Compounds |
| US8546413B2 (en) | 2009-06-15 | 2013-10-01 | Nerviano Medical Sciences S.R.L. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
| ES2655264T3 (es) | 2012-01-28 | 2018-02-19 | Merck Patent Gmbh | Derivados de triazolo[4,5-d]pirimidina |
| US20150051202A1 (en) | 2012-03-07 | 2015-02-19 | Merck Patent Gmbh | Triazolopyrazine derivatives |
| WO2014031928A2 (en) | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
| ES2755772T3 (es) | 2012-11-07 | 2020-04-23 | Nerviano Medical Sciences Srl | Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas |
| EP2964648B1 (en) | 2013-03-05 | 2016-11-16 | Merck Patent GmbH | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| AU2014224975B2 (en) | 2013-03-05 | 2017-09-14 | Merck Patent Gmbh | Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer |
| CN105732614B (zh) | 2014-12-09 | 2018-06-12 | 中国科学院广州生物医药与健康研究院 | 磺酰胺基芳基炔类化合物及其用途 |
| CN104829613B (zh) | 2015-04-13 | 2020-06-09 | 赤峰蒙广生物科技有限公司 | 二芳基取代的吡唑并环类衍生物、其制备方法及其在医药领域的应用 |
| CN108473476B (zh) | 2016-10-13 | 2021-02-19 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的炔基杂环类化合物 |
| JP7229257B2 (ja) | 2018-01-29 | 2023-02-28 | メルク パテント ゲーエムベーハー | Ｇｃｎ２阻害剤およびその使用 |
| BR112020015396A2 (pt) | 2018-01-29 | 2020-12-08 | Merck Patent Gmbh | Inididores de gcn2 e usos dos mesmos |
| EP3802544A1 (en) | 2018-06-05 | 2021-04-14 | RAPT Therapeutics, Inc. | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses |
| WO2021155253A1 (en) | 2020-01-31 | 2021-08-05 | Atomwise Inc. | Anat inhibitors and methods of use thereof |
| JP2023514328A (ja) | 2020-02-17 | 2023-04-05 | アレスタ・セラピューティクス・ベスローテン・フェンノートシャップ | Ｇｃｎ２モジュレーター化合物 |
| WO2021222147A1 (en) | 2020-04-27 | 2021-11-04 | Hibercell, Inc. | Heterocyclic gcn2 modulators |
| GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
| IL302807A (en) | 2020-11-18 | 2023-07-01 | Deciphera Pharmaceuticals Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
| BR112023014723A2 (pt) | 2021-01-22 | 2023-10-03 | Hibercell Inc | Compostos moduladores de gcn2 e usos dos mesmos |
| US20240150345A1 (en) | 2021-01-22 | 2024-05-09 | Hibercell, Inc. | Gcn2 modulating compounds and uses thereof |
-
2020
- 2020-06-09 GB GBGB2008749.0A patent/GB202008749D0/en not_active Ceased
-
2021
- 2021-06-09 EP EP21735355.6A patent/EP4161915A1/en active Pending
- 2021-06-09 WO PCT/GB2021/051428 patent/WO2021250399A1/en not_active Ceased
- 2021-06-09 US US18/001,317 patent/US20230271939A1/en active Pending
- 2021-06-09 KR KR1020237000394A patent/KR20230058042A/ko active Pending
- 2021-06-09 MX MX2022015516A patent/MX2022015516A/es unknown
- 2021-06-09 JP JP2022576040A patent/JP2023529926A/ja active Pending
- 2021-06-09 IL IL298860A patent/IL298860B1/en unknown
- 2021-06-09 BR BR112022025147A patent/BR112022025147A2/pt unknown
- 2021-06-09 CA CA3181909A patent/CA3181909A1/en active Pending
- 2021-06-09 CN CN202180058556.4A patent/CN116113629B/zh active Active
- 2021-06-09 CN CN202411827368.5A patent/CN119661503A/zh active Pending
- 2021-06-09 AU AU2021289535A patent/AU2021289535A1/en active Pending
-
2023
- 2023-03-28 US US18/191,772 patent/US11945799B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018030466A1 (ja) * | 2016-08-10 | 2018-02-15 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2020210828A1 (en) * | 2019-04-12 | 2020-10-15 | Hibercell, Inc. | (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022015516A (es) | 2023-03-22 |
| CA3181909A1 (en) | 2021-12-16 |
| WO2021250399A1 (en) | 2021-12-16 |
| AU2021289535A1 (en) | 2023-02-09 |
| GB202008749D0 (en) | 2020-07-22 |
| US20230271939A1 (en) | 2023-08-31 |
| KR20230058042A (ko) | 2023-05-02 |
| US20230250082A1 (en) | 2023-08-10 |
| US11945799B2 (en) | 2024-04-02 |
| CN119661503A (zh) | 2025-03-21 |
| CN116113629B (zh) | 2024-12-31 |
| IL298860B1 (en) | 2026-04-01 |
| CN116113629A (zh) | 2023-05-12 |
| IL298860A (en) | 2023-02-01 |
| EP4161915A1 (en) | 2023-04-12 |
| BR112022025147A2 (pt) | 2023-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11945799B2 (en) | 4-ethynylpyridine derivatives useful as GCN2 inhibitors | |
| ES2900184T3 (es) | Combinaciones terapéuticas de un inhibidor de BTK y un inhibidor de BCL-2 | |
| CA3166554A1 (en) | Benzamide containing compounds for modulating brg1- or brm-associated factors_________________________________________________ | |
| TW200413377A (en) | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
| CN113366008B (zh) | 一种cd73抑制剂，其制备方法和应用 | |
| WO2022155202A1 (en) | Fused heterocycles and uses of same | |
| TW202406542A (zh) | Kif18a抑制劑及其用途 | |
| AU2023269328A1 (en) | Gcn2 inhibitorr | |
| CN113717245A (zh) | 含有2,8,9-三取代-9h-嘌呤结构片段的egfr降解剂及其盐和应用 | |
| TW202313629A (zh) | 化合物及其用途 | |
| CN115443275A (zh) | 作为acss2抑制剂的被酰胺官能取代的缩合的吡啶衍生物 | |
| CN115335371B (zh) | 四唑衍生物 | |
| JP6073480B2 (ja) | ＰＩ３Ｋおよび／またはｍＴＯＲ阻害剤 | |
| WO2023111543A1 (en) | 4-(2-pyrazolo[3,4-b]pyridine-5-yl)ethynyl-2-pyridine derivatives useful as gcn2 inhibitors | |
| CN105121442B (zh) | PI3K和/或mTOR抑制剂的前药 | |
| WO2026080226A1 (en) | Tricyclic derivatives, compositions and methods thereof | |
| US20240425497A1 (en) | Cbl-b Inhibitors and Methods of Use Thereof | |
| HK40052933B (en) | Cd73 inhibitor, preparation method therefor and application thereof | |
| HK1210464B (en) | Pi3k and/or mtor inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240610 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240610 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240726 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241203 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250424 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250507 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250618 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20251107 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260204 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260401 |